AIP
RARE icon

Ameritas Investment Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Ameritas Investment Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,245
Closed -$597K – 3198
2021
Q1 		$597K Sell
5,245
-47
-0.9% -$6.4K 0.02% 739
2020
Q4 		$733K Buy
5,292
+391
+8% +$46.4K 0.03% 661
2020
Q3 		$403K Sell
4,901
-110
-2% -$9.12K 0.02% 771
2020
Q2 		$392K Buy
5,011
+157
+3% +$10.4K 0.02% 776
2020
Q1 		$216K Buy
4,854
+208
+4% +$10.8K 0.01% 896
2019
Q4 		$198K Hold
4,646
– – 0.01% 1093
2019
Q3 		$199K Hold
4,646
– – 0.01% 1055
2019
Q2 		$295K Buy
4,646
+293
+7% +$18.6K 0.01% 879
2019
Q1 		$302K Buy
4,353
+400
+10% +$22.9K 0.01% 865
2018
Q4 		$172K Hold
3,953
– – 0.01% 1045
2018
Q3 		$302K Hold
3,953
– – 0.01% 878
2018
Q2 		$304K Buy
3,953
+191
+5% +$12.3K 0.01% 864
2018
Q1 		$192K Buy
3,762
+288
+8% +$14.5K 0.01% 1096
2017
Q4 		$161K Hold
3,474
– – 0.01% 1210
2017
Q3 		$198K Hold
3,474
– – 0.01% 1070
2017
Q2 		$216K Buy
3,474
+248
+8% +$14.9K 0.01% 1022
2017
Q1 		$219K Buy
3,226
+115
+4% +$8.76K 0.01% 1007
2016
Q4 		$219K Hold
3,111
– – 0.01% 997
2016
Q3 		$221K Buy
+3,111
New +$199K 0.01% 965
2016
Q1 		– Sell
-3,021
Closed -$339K – 1184
2015
Q4 		$339K Hold
3,021
– – 0.02% 756
2015
Q3 		$291K Buy
3,021
+250
+9% +$28.6K 0.02% 781
2015
Q2 		$284K Buy
+2,771
New +$215K 0.02% 838

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ameritas Investment Partners's RARE Position: Q2 2021 in Review

Ameritas Investment Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 5,245 shares — an estimated $597K sold.

Ameritas Investment Partners first reported a position in RARE in Q2 2015 and held it in 22 quarters. The position peaked at $733K in Q4 2020. 241 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

  • Ameritas Investment Partners reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Partners sold 5,245 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $597K.
  • Ameritas Investment Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and held it in 22 quarters.
  • Ameritas Investment Partners's Ultragenyx Pharmaceutical position peaked at $733K in Q4 2020.
  • 241 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.